Stay updated on Lazertinib vs Intravenous Amivantamab in Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the Lazertinib vs Intravenous Amivantamab in Lung Cancer Clinical Trial page.

Latest updates to the Lazertinib vs Intravenous Amivantamab in Lung Cancer Clinical Trial page
- Check4 days agoChange DetectedThe PALOMA-3 page shows updated study record timestamps with new entries on 2025-12-04 and 2025-12-08 and removal of earlier entries (2025-11-10, 2025-11-06, 2025-11); no changes to study design, eligibility criteria, or outcomes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedAdded Liuchow, China (545026) as a recruitment site and removed Liuzhou, China (545026). The page revision was updated from v3.3.1 to v3.3.2.SummaryDifference0.0%

- Check25 days agoChange DetectedAdded a note that publications are automatically filled from PubMed and may not all be about the study, and updated the page revision to v3.3.1. Removed the older PubMed-listed publication description and the previous revision reference (v3.2.0).SummaryDifference0.0%

- Check32 days agoChange DetectedTaiwan site entry changed from 'Tainan City' to 'Tainan' with the same postal code 70403; removal of a government funding status notice from the page.SummaryDifference0.2%

- Check46 days agoChange DetectedNo additions or deletions were detected on the Study Details page; the content appears unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check61 days agoChange DetectedAdds more recent date references (10/9/2025, 10/10/2025, and 2025-10) and removes earlier September 2025 references (2025-09-15, 2025-09-11, and 2025-09).SummaryDifference0.2%

Stay in the know with updates to Lazertinib vs Intravenous Amivantamab in Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lazertinib vs Intravenous Amivantamab in Lung Cancer Clinical Trial page.